Vascularized regenerative biomaterials for medical devices and cell therapy

用于医疗器械和细胞治疗的血管化再生生物材料

• 批准号: 493837-2016
• 负责人: Sefton, Michael
• 金额: $ 11.43万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Collaborative Health Research Projects
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=621882
• 关键词: Vascularized; regenerative; biomaterials; medical; devices

While islet transplantation is a promising treatment for the 1% of Canadians who live with insulin dependent (type 1)diabetes, the majority of islets (perhaps 60%) in current protocols are lost almost immediately upon transplantation. This isdue to inflammatory responses and the lack of blood vessels near the islet which impairs islet survival and function. We havediscovered a unique material that induces the formation of blood vessels and we propose to use this material (as a coatingor as an degradable gel) to generate a medical device (particularly a cell delivery device) that is more functional than iscurrently attainable with conventional materials. The successful use of implantable medical devices is built on thebiocompatibility of inert biomaterials that generate a fibrotic response which isolates the implant from the patient and ensuresthe device is safe. However, this fibrosis precludes the successful use of other devices such as glucose sensors or cellpouches for cell delivery (especially pancreatic islets for diabetes). In this proposal the focus is on a unique Cell PouchSystem produced by an Ontario company, Sernova which is being developed for pancreatic islet delivery to treat diabetes.The unique vascular regenerating biomaterial, based on MAA (methacrylic acid) is expected to enhance vascularization inand around the pouch and so accelerate the ability of islets to respond to elevated glucose levels in diabetic patients.Furthermore the MAA materials (and particularly the degradable gel) are expected to simplify the clinical use (and efficacy ofthe Cell Pouch because it is expected that the device can be implanted and loaded with islets in one step.

虽然胰岛移植是一种有希望的治疗1%的加拿大人谁生活与胰岛素依赖型（1型）糖尿病，大多数胰岛（也许60%）在目前的协议几乎立即失去移植后。这是由于炎症反应和胰岛附近缺乏血管，这损害了胰岛的存活和功能。我们已经发现了一种独特的材料，可以诱导血管的形成，我们建议使用这种材料（作为涂层或作为可降解凝胶）来生产一种医疗设备（特别是细胞输送设备），这种设备比目前使用传统材料获得的功能更强大。植入式医疗器械的成功使用是建立在惰性生物材料的生物相容性基础上的，惰性生物材料会产生纤维化反应，将植入物与患者隔离，并确保器械安全。然而，这种纤维化阻碍了其他装置的成功使用，例如葡萄糖传感器或细胞袋用于细胞递送（特别是用于糖尿病的胰岛）。在这个提案中，重点是由安大略公司Sernova生产的独特的Cell PouchSystem，该公司正在开发用于胰岛输送以治疗糖尿病的独特的血管再生生物材料，基于MAA预期MAA材料（甲基丙烯酸）增强囊内和囊周围的血管形成，从而加速糖尿病患者中胰岛对升高的葡萄糖水平作出反应的能力。（并且特别是可降解凝胶）预期简化细胞袋的临床使用（和功效），因为预期该装置可以在一个步骤中植入和装载胰岛。